论文部分内容阅读
目的探讨聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型病毒性肝炎的疗效。方法选取2012年6月—2014年2月中牟县卫生防疫站收治的慢性丙型病毒性肝炎患者66例,随机分为研究组与对照组,各33例。研究组患者予以聚乙二醇干扰素α-2a联合利巴韦林治疗,对照组患者予以重组人干扰素α-2b联合利巴韦林治疗。观察两组患者血清学指标、丙氨酸氨基转移酶(ALT)复常与血清HCV-RNA阴转情况及不良反应发生情况。结果研究组患者早期病毒学应答(EVR)、结束时病毒学应答(ETVR)、持续病毒学应答(SVR)率高于对照组(P<0.05);研究组患者ALT复常与HCV-RNA阴转率高于对照组(P<0.05);两组患者均未发生严重不良反应。结论聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型病毒性肝炎的疗效显著,不良反应少,安全性高。
Objective To investigate the efficacy of peginterferon alfa-2a combined with ribavirin in the treatment of chronic hepatitis C virus. Methods Sixty-six patients with chronic hepatitis C who were admitted to Zhongmu County Health and Anti-Epidemic Station from June 2012 to February 2014 were randomly divided into study group and control group, with 33 cases in each group. Patients in the study group were treated with peginterferon alfa-2a plus ribavirin, and patients in the control group were treated with recombinant interferon alpha-2b plus ribavirin. Serum parameters, alanine aminotransferase (ALT) abnormalities, serum HCV-RNA negative conversion and adverse reactions in both groups were observed. Results In the study group, the rates of early virological response (EVR), end of virological response (ETVR), and sustained virological response (SVR) were higher in the study group than in the control group (P <0.05) Transfer rate was higher than the control group (P <0.05); no serious adverse reactions occurred in both groups. Conclusion Pegylated interferon α-2a combined with ribavirin has significant curative effect on chronic hepatitis C with less adverse reactions and high safety.